Eritoran

Cat. No.:	HY-105070
CAS No.:	185955-34-4
Molecular Formula:	$C_{66}H_{126}N_2O_{19}P_2$
Molecular Weight:	1313.66
Target:	EBV; Toll-like Receptor (TLR)
Pathway:	Anti-infection; Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Eritoran is a Toll-like receptor 4 (TLR4) antagonist. Eritoran protects mice against lethal influenza virus infection, such as Ebola virus (EBOV), Marburg virus (MARV). Eritoran decreases the level of granulocytosis, may alleviate the severity of the "cytokine storm". Eritoran inhibits pathogenesis of filovirus infection[1].
IC_{50} & Target	TLR4
In Vivo	Eritoran (233 μg/mouse; i.p.; 10 days) protects mouse from EBOV lethal infection, results 70% survived until the end of the study[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6J mice challenged with lethal EBOV[1]
Dosage:	233 μg/mouse
Administration:	Intraperitoneal injection; 10 days
Result:	Reduced granulocytosis and results in a higher percentage of activated CD11b+ Ly6G/Ly6C+ neutrophils. Dramatically reduced the levels of IFN-γ-secreting CD8+ and CD4+ T cells and IL-17A-secreting CD4+ T cells.

REFERENCES

[1]. Younan P, et al. The Toll-Like Receptor 4 Antagonist Eritoran Protects Mice from Lethal Filovirus Challenge. mBio. 2017 Apr 25;8(2):e00226-17.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA